Dr. Riffer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7600 N 15th St
#190
Phoenix, AZ 85020Phone+1 602-200-3800Fax+1 602-200-3838
Education & Training
University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 1986 - 1989
University of Illinois College of MedicineClass of 1986
Certifications & Licensure
AZ State Medical License 1988 - 2026
TX State Medical License 1990 - 1995- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Aprima EHR, Aprima Medical Software, Inc., 2012-2013
Clinical Trials
- A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease Start of enrollment: 2011 Nov 01
- A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Start of enrollment: 2014 Oct 01
- Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- 16 citationsOnce daily clarithromycin extended-release vs twice- daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded studyErnie Riffer, Joy Spiller, Robert H. Palmer, Virginia Shortridge, Todd A. Busman
Current Medical Research and Opinion. 2005-01-01 - 32 citationsRandomized Double-Blind Study Comparing 3- and 6-Day Regimens of Azithromycin with a 10-Day Amoxicillin-Clavulanate Regimen for Treatment of Acute Bacterial SinusitisDan C. Henry, Ernie Riffer, William N. Sokol, Naumann I. Chaudry, Robert N. Swanson
Antimicrobial Agents and Chemotherapy. 2003-09-01 - 43 citationsComparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in womenDan C. Henry, Robert B. Bettis, Ernie Riffer, Daniel Haverstock, Steven F. Kowalsky
Clinical Therapeutics. 2002-12-01
Press Mentions
Inovio’s Recent Data Fails to Impress Some Analysts but Overall Data Looks Promising & Study Backed by Department of DefenseDecember 29th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
